Millendo Therapeutics to Participate in Upcoming Investor Conferences
ANN ARBOR, Mich.--(BUSINESS WIRE)--Aug 10, 2018--Millendo Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases, today announced that Julia C. Owens, Ph.D., President and Chief Executive Officer, will participate in the following August conferences:2018 Oppenheimer Newport Summit for Revolutionary Biotechnology on Monday, August 13, 2018 in Newport, RI, where the Company will host investor meetings 2018 Wedbush PacGrow Healthcare Conference, where the Company will provide a corporate overview and pipeline update on Wednesday, August 15, 2018 at 9:45 AM ET in New York, NY
About Millendo Therapeutics, Inc. Millendo Therapeutics is focused on developing novel treatments for orphan endocrine diseases. The Company’s objective is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of diseases where there is a significant unmet medical need. The Company is currently advancing livoletide for the treatment of Prader-Willi syndrome and nevanimibe for the treatment of classic congenital adrenal hyperplasia and endogenous Cushing’s syndrome. For more information, please visit www.millendo.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180810005059/en/
CONTACT: Media Contact:
MacDougall Biomedical Communications
Cammy Duong, 781-591-3443
Stern Investor Relations
Stephen Rutman, 212-362-1200
KEYWORD: UNITED STATES NORTH AMERICA MICHIGAN NEW YORK RHODE ISLAND
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY INFECTIOUS DISEASES PHARMACEUTICAL
SOURCE: Millendo Therapeutics, Inc.
Copyright Business Wire 2018.
PUB: 08/10/2018 08:00 AM/DISC: 08/10/2018 08:00 AM